Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 6.8% in March

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) saw a significant increase in short interest in March. As of March 31st, there was short interest totalling 14,200 shares, an increase of 6.8% from the March 15th total of 13,300 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average trading volume of 18,300 shares, the short-interest ratio is currently 0.8 days.

Armata Pharmaceuticals Stock Down 21.9 %

Shares of NYSEAMERICAN ARMP opened at $2.50 on Thursday. The stock has a market capitalization of $90.38 million, a price-to-earnings ratio of -1.26 and a beta of 0.85. Armata Pharmaceuticals has a 1 year low of $1.07 and a 1 year high of $5.26.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.55) earnings per share (EPS) for the quarter. The firm had revenue of $1.53 million during the quarter, compared to the consensus estimate of $0.68 million. Armata Pharmaceuticals had a negative return on equity of 280.95% and a negative net margin of 1,524.51%. On average, sell-side analysts predict that Armata Pharmaceuticals will post -1.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Armata Pharmaceuticals in a research report on Friday, March 22nd.

Institutional Trading of Armata Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp bought a new stake in shares of Armata Pharmaceuticals during the first quarter valued at approximately $95,000. Jane Street Group LLC bought a new stake in shares of Armata Pharmaceuticals during the fourth quarter valued at approximately $25,000. HRT Financial LP bought a new stake in shares of Armata Pharmaceuticals during the fourth quarter valued at approximately $52,000. Renaissance Technologies LLC raised its stake in shares of Armata Pharmaceuticals by 5.6% during the fourth quarter. Renaissance Technologies LLC now owns 73,696 shares of the company’s stock valued at $91,000 after acquiring an additional 3,900 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Armata Pharmaceuticals by 51.9% during the third quarter. Vanguard Group Inc. now owns 90,969 shares of the company’s stock valued at $273,000 after acquiring an additional 31,079 shares in the last quarter. Institutional investors own 3.57% of the company’s stock.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.